Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
27. Gathe J, Jr., Badaro R, Grimwood A, Abrams L, Klesczewski K, Cross A, et al. Antiviral<br />
activity of enteric-coated didanosine, stavudine, and n<strong>el</strong>finavir versus zidovudine plus<br />
<strong>la</strong>mivudine and n<strong>el</strong>finavir. J Acquir Immune Defic Syndr 2002;31(4):399-403.<br />
28. Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, et al. A randomised, open-<strong>la</strong>b<strong>el</strong><br />
comparison of three highly active antiretroviral therapy regimens including two nucleosi<strong>de</strong><br />
analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.<br />
AIDS 2000;14(9):1171-80.<br />
29. Geijo Martínez MP MMM, Solera Santos J, Barberá Farré JR, Rodríguez Zapata M, Marcos<br />
Sánchez F, Martínez Alfaro E, Cuadra García-Tenorio F, Sanz Moreno J, Moreno Mendaña<br />
JM, Beato Pérez JL, Sanz Sanz J; GECMEI. Ensayo clínico comparativo <strong>de</strong> eficacia y<br />
seguridad <strong>de</strong> cuatro pautas <strong>de</strong> tratamiento <strong>antirretroviral</strong> <strong>de</strong> alta eficacia (TARGA) en<br />
pacientes con <strong>infección</strong> <strong>por</strong> <strong>VIH</strong> avanzada [Test comparative clinical efficacy and safety<br />
of four treatment gui<strong>de</strong>lines highly active antiretroviral (TARGA) in patients with advanced<br />
HIV infection]. Rev Clin Esp 2006;206:67-76.<br />
30. Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG,<br />
et al. A prospective, 96-week study of the impact of Trizivir, Combivir/n<strong>el</strong>finavir, and<br />
<strong>la</strong>mivudine/stavudine/n<strong>el</strong>finavir on lipids, metabolic parameters and efficacy in<br />
antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 2006;7(2):85-98.<br />
31. Li T, Dai Y, Kuang J, Jiang J, Han Y, Qiu Z, et al. Three generic nevirapine-based<br />
antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.<br />
PLoS ONE 2008;3(12):e3918.<br />
32. Robbins GK, De Grutto<strong>la</strong> V, Shafer RW, Smeaton LM, Sny<strong>de</strong>r SW, Pettin<strong>el</strong>li C, et al.<br />
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N<br />
Engl J Med 2003;349(24):2293-303.<br />
33. Squires KE, Gulick R, Tebas P, Santana J, Mu<strong>la</strong>novich V, C<strong>la</strong>rk R, et al. A comparison of<br />
stavudine plus <strong>la</strong>mivudine versus zidovudine plus <strong>la</strong>mivudine in combination with indinavir<br />
in antiretroviral naive individuals with HIV infection: s<strong>el</strong>ection of thymidine analog regimen<br />
therapy (START I). AIDS 2000;14(11):1591-600.<br />
34. The Adult Antiretroviral Treatment and Resistance Study Tshepo [database on the Internet]<br />
2009 [cited November 11, 2009]. Avai<strong>la</strong>ble from: http://clinicaltrials.gov/ct2/show/<br />
NCT00197613?term=Tshepo&rank=1.<br />
35. Gal<strong>la</strong>nt JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy<br />
and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive<br />
patients: a 3-year randomized trial. JAMA 2004;292(2):191-201.<br />
36. Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, et al. High rate of early<br />
virological failure with the once-daily tenofovir/<strong>la</strong>mivudine/nevirapine combination in naive<br />
HIV-1-infected patients. J Antimicrob Chemother 2009;63(2):380-8.<br />
133
Change language